RLX, CAS [[4425-23-4]]

Product Overview

• Article Name: RLX, CAS [[4425-23-4]]
• Biozol Catalog Number: MCE-HY-116604
• Supplier Catalog Number: HY-116604
• Alternative Catalog Number: MCE-HY-116604-1MG,MCE-HY-116604-10MG,MCE-HY-116604-100MG,MCE-HY-116604-25MG,MCE-HY-116604-50MG,MCE-HY-116604-5MG
• Manufacturer: MedchemExpress
• Category: Biochemikalien
• Alternative Names: PD 139530

Product Description

RLX (PD 139530) is a PI3K/Akt/FoxO3a signaling inhibitor, possessing significant therapeutic potential in experimental colon cancer. RLX can effectively modulate the tumor microenvironment, enhancing the efficacy of cancer immunotherapy. RLX demonstrates the ability to improve the retention time of therapeutic agents within the tumor microenvironment by utilizing advanced nanoparticle delivery systems. RLX can be integrated with various treatment modalities, such as chemotherapy and radiotherapy, to enhance overall tumor therapy effectiveness[1].

Product Properties

• Molecular Weight: 214.26
• CAS Number: [4425-23-4]
• Formula: C13H14N2O
• Target: Akt,PI3K

Application Notes

• Application Notes: MCE Product type: Reference compound